TYME News and Press, Tyme Technologies Inc. From 02/08/21

Are Biotech Penny Stocks Part Of Your Strategy In 2021? It’s February 2021, and the markets are at all-time highs. Trading volumes remain strong, and penny stocks continue captivating retail traders. We also see several hot industries fanning the flames of this market rally. ...

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per shar...

Shares of Tyme Technologies (NASDAQ: TYME) were down by 36% as of 1:05 p.m. EST today, after the company reported fiscal third-quarter results. Tyme also launched  an at-the-market (ATM) stock offering. The clinical-stage biotech company said that it presented prelimina...

Gainers: ATA Creativity Global (AACG) +204%.Anavex Life Sciences (AVXL) +81%.Lizhi (LIZI) +76%.CPS Technologies (CPSH) +48%.Annovis Bio (ANVS) +43%.Sify Technologies (SIFY) +42%.Tian Ruixiang (TIRX) +40%.Cyclerion Therapeutics (CYCN) +39%.Cyclo Therapeutics (CYTH) +33%.Ato...

Tyme Technologies (TYME) nearly doubled in value yesterday after the announcement of a patent win related to the company's experimental antiviral therapy for COVID-19, TYME-19.Then an equity offering of 40M common shares was announced to raise $100M gross proceeds, and the...

Gainers: Anavex Life Sciences (AVXL) +94%, Annovis Bio (ANVS) +50%, Atossa Therapeutics (ATOS) +40%, Cyclerion Therapeutics (CYCN) +40%, Cyclo Therapeutics (CYTH) +33%.Losers: Tyme Technologies (TYME) -36%, Isoray (ISR) -19%, Lannett...

Tyme Technologies (TYME): FQ3 Cash and equivalents ~$13.5M.Operational cash burn rate was $5.9M compared to $6.6M for the FQ2 and $4.5M for FQ3 2020.Shares -27.76% PM.Press Release For further details see: Tyme Technologies reports FQ3 results

Announced Richie Cunningham as new Chief Executive Officer Presented data from TYME-88-Panc Study at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium Continued enrolling patients in multicenter randomized controlled TYME-88-Panc pivotal trial e...

Tyme Technologies (TYME) inks agreements with institutional investors for the sale of 40M common shares at $2.50/share in a registered direct offering priced at-the-market.Expected gross proceeds are $100M. Net proceeds will be used for development of clinical and preclinical assets, for gene...

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM ), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the ...